SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-059792
Filing Date
2023-11-07
Accepted
2023-11-07 08:34:11
Documents
60
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-20230930.htm   iXBRL 10-Q 2006636
2 EX-31.1 inzy-ex31_1.htm EX-31.1 18084
3 EX-31.2 inzy-ex31_2.htm EX-31.2 18892
4 EX-32.1 inzy-ex32_1.htm EX-32.1 10443
5 EX-32.2 inzy-ex32_2.htm EX-32.2 10631
  Complete submission text file 0000950170-23-059792.txt   6856313

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT inzy-20230930_cal.xml EX-101.CAL 39169
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20230930_lab.xml EX-101.LAB 416530
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20230930.xsd EX-101.SCH 42010
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT inzy-20230930_def.xml EX-101.DEF 154003
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20230930_pre.xml EX-101.PRE 299240
54 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20230930_htm.xml XML 1039961
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 231381819
SIC: 2834 Pharmaceutical Preparations